Multi-center comparative study of methylprednisolone and dexamethasone in treatment of all-frequency sudden hearing loss.

Yuanyuan Jing; Dayong Wang; Zhaomin Fan; Xiulan MA; Mingming Wang; Lei XU; Xinjia Zhou; Xin XI; Liming YU; Haibo Wang; Lisheng YU; Email: Yulish68@163com; Qiuju Wang; Email: Wqcr@263net

Return

Multi-center comparative study of methylprednisolone and dexamethasone in treatment of all-frequency sudden hearing loss.

Author: Yuanyuan JING ¹ ; Dayong WANG ² ; Zhaomin FAN ³ ; Xiulan MA ⁴ ; Mingming WANG ³ ; Lei XU ³ ; Xinjia ZHOU ⁴ ; Xin XI ² ; Liming YU ² ; Haibo WANG ³ ; Lisheng YU ⁵ ; Email: YULISH68@163.COM. ; Qiuju WANG ⁶ ; Email: WQCR@263.NET.
Author Information

1. Department of Otorhinolaryngology, Peking University People's Hospital, Beijing 100044, China.
2. Department of Otorhinolaryngology Head and Neck Surgery, Institute of Otorhinolaryngology, General Hospital of People's Liberation Army, Beijing 100853, China.
3. Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
4. Department of Otorhinolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
5. Department of Otorhinolaryngology, Peking University People's Hospital, Beijing 100044, China
6. Department of Otorhinolaryngology Head and Neck Surgery, Institute of Otorhinolaryngology, General Hospital of People's Liberation Army, Beijing 100853, China
Publication Type:Journal Article
MeSH: Audiometry, Pure-Tone; Dexamethasone; therapeutic use; Glucocorticoids; therapeutic use; Hearing Loss, Sudden; drug therapy; Humans; Methylprednisolone; therapeutic use; Prospective Studies; Speech Perception
From: Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2015;50(7):536-539
CountryChina
Language:Chinese
Abstract:
OBJECTIVEThrough a prospective cohort study, to assess the clinical efficacy of methylprednisolone (MP) and dexamethasone (DXM) in treatment of all-frequency sudden hearing loss.
METHODSA total of 76 cases of all-frequency sudden hearing loss were included in this study and divided into two groups. The MP group (n = 40) was treated with MP 40 mg qd, for 5 days, combined with conventional treatment. The DXM group (n = 36) was treated with DXM 10 mg qd, for 5 days, combined with conventional treatment. The total period of treatment was 14 days.
RESULTSAfter the treatment for 14 days, in the MP group,17 cases were cured (42.5%), 7 cases were markedly improved (17.5%), 9 cases were effective (22.5%), and 7 cases were invalid (17.5%), the total effective rate was 82.5%. As for the patients in the DXM group, 13 cases were cured (36.1%), 6 cases were markedly improved (16.7%), 8 cases were effective (24.2%), and 9 cases were invalid (25%), the total effective rate was 75.0%. The pure tone audiometry in all-frequency was improved (31.5 ± 17.8) dB in the MP group, and (33.1 ± 24.2) dB in the DXM group. The speech recognition rate was improved (41.7 ± 29.8) %, and (42.0 ± 39.1) % in the DXM group. There were no significant differences between two groups.
CONCLUSIONThere is no significant difference of therapeutic efficacy between the low-dose MP group and High-dose DXM group.